Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Reporting period and context: The filing reports events beginning March 22, 2022. It was signed and filed on March 28, 2022, under Item 5.02 concerning executive officer appointments and transition arrangements. The company is a Delaware biotechnology company whose common stock trades on Nasdaq under the symbol PHAT.
Executive Appointment
- Molly Henderson was appointed Chief Financial and Business Officer, effective April 5, 2022.
- She will also become the company’s principal financial and accounting officer for SEC filings effective April 5, 2022.
- Henderson previously served as CFO of Urogen Pharma Ltd. and held senior finance roles at Advaxis, Iovance Biotherapeutics, VirtualScopics, and other companies.
- The filing states that Henderson has no family relationship with any director or executive officer and no reportable related-party interest under Item 404(a) of Regulation S-K.
Compensation and Equity Arrangements
- Initial annual base salary: $480,000.
- Target annual bonus: 45% of annual base salary.
- Upon commencement, Henderson will receive options to purchase 100,000 common shares. The options will have a ten-year term, an exercise price equal to fair market value on the grant date, and four-year vesting, with 25% vesting after one year and the remainder vesting monthly over the following three years.
- She will also receive 20,000 restricted stock units, vesting in equal one-third installments on the first, second, and third anniversaries, subject to continued service.
- Amounts previously earned, including unpaid salary and accrued unused vacation, remain payable upon termination.
Severance and Change-in-Control Terms
- For termination without cause or resignation for good reason outside a change-in-control period, Henderson may receive nine months of base-salary continuation, specified bonus payments, COBRA premium payments subject to stated conditions, and acceleration of equity awards that would have vested during the severance period.
- For qualifying termination during the period beginning three months before and ending 24 months after a change in control, the salary-continuation period increases to 12 months, the bonus treatment changes as specified in the employment letter, and outstanding unvested equity awards become fully vested subject to the stated conditions.
- Benefits are subject to execution of a release of claims, return of company property, compliance with post-termination obligations, and resignation from company positions.
Transition of Chief Accounting Officer
- Phathom and Anthony Guzzo, the company’s Chief Accounting Officer and acting principal financial officer, entered into a transition services agreement effective March 22, 2022.
- Guzzo’s last day of full-time employment is expected to be on or around August 15, 2022.
- The company extended the vesting period for certain performance stock units and the exercise period for Guzzo’s vested options through December 31, 2022.
- The filing states that Guzzo’s departure was not related to disagreements concerning operations, financial statements, internal controls, auditors, policies, or practices.
Financial Metrics, Outlook, and Risks
This Form 8-K does not provide revenue, profit, cash flow, margins, debt, liquidity, operating guidance, or other period-specific financial metrics. It also does not provide new business or clinical guidance. The principal disclosed matters are executive succession, compensation, equity awards, severance obligations, and the transition of the acting principal financial officer.
Important Facts for Investors to Verify
- Confirm Henderson’s April 5, 2022 start date and effective date as principal financial and accounting officer.
- Review the employment letter, which the company stated would be filed with its Form 10-Q for the quarter ended March 31, 2022.
- Assess the potential dilution and expense implications of the 100,000 stock options and 20,000 RSUs.
- Review the conditions and potential cost of Henderson’s severance and change-in-control benefits.
- Monitor Guzzo’s transition through his expected final full-time employment date and the December 31, 2022 option-exercise extension.